New York, NY – For decades, the role of regulatory T (Treg) cells in cancer has presented a puzzling paradox, particularly in colorectal cancer (CRC). While these immune cells, known for their ability to suppress immune responses, are typically associated with worse outcomes in most solid tumors, their abundance in colorectal cancer has long been linked to improved patient survival. This perplexing exception has baffled researchers, obscuring potential therapeutic pathways.
Now, a groundbreaking study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has finally demystified this anomaly. Published in the prestigious scientific journal Immunity, the research reveals that not all Treg cells are created equal. Instead, their impact on colorectal cancer depends critically on their distinct subtypes, with some actively restraining tumor growth while others accelerate it. This pivotal discovery promises to revolutionize immunotherapy for the most common forms of colorectal cancer and potentially extend its reach to other barrier-tissue cancers, including those of the skin, mouth, throat, and stomach.
The Core Discovery: Two Sides of the Treg Coin
The central finding of the MSK study is a paradigm shift in understanding Treg cell function within the tumor microenvironment. "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
This revelation clarifies why a blanket association between Treg cells and prognosis has been misleading in CRC. The research demonstrates that the sheer number of Treg cells is less important than the balance and specific functions of these newly identified subtypes. This nuanced understanding opens the door to highly targeted immunotherapies that could selectively neutralize harmful Treg cells while preserving or even enhancing the beneficial ones, offering a more effective and less toxic treatment strategy.
Decades of Groundwork Culminate in a Breakthrough
This seminal work is the culmination of more than two decades of dedicated research by Dr. Rudensky, a globally recognized authority on regulatory T cells. His pioneering investigations have been instrumental in defining Treg cells’ fundamental role in maintaining "immune tolerance" – the delicate balance that prevents the immune system from attacking the body’s own healthy tissues, beneficial microbes, and harmless environmental substances. Over the years, Dr. Rudensky’s lab has systematically elucidated the complex mechanisms governing Treg cell development, function, and their intricate influence on disease progression, including cancer.
The current study, led by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, the study’s other senior author, builds directly upon this extensive foundational knowledge. It represents a significant leap forward in translating basic immunological insights into clinically actionable strategies, particularly for a disease like colorectal cancer that remains a major global health challenge.
Focusing on the Most Prevalent Form of Colorectal Cancer
Colorectal cancer stands as the second leading cause of cancer-related death when statistics for men and women are combined, according to the American Cancer Society. A substantial majority—approximately 80% to 85%—of all colorectal cancers fall into a category known as microsatellite stable (MSS) with proficient mismatch repair (MMRp). These tumors are characterized by relatively stable DNA and, critically, have historically shown poor responsiveness to a promising class of treatments: checkpoint inhibitor immunotherapies.
This poor response contrasts sharply with a smaller subset of colorectal cancers that exhibit high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). Earlier research, also conducted at MSK, demonstrated that these MSI-H/MMRd tumors can often be effectively managed with immunotherapy alone, frequently allowing patients to forgo arduous surgeries, chemotherapy, and radiation. The discrepancy highlighted an urgent need for novel approaches for the vast majority of CRC patients whose tumors are MSS/MMRp. It is precisely this challenging, prevalent group that the MSK team’s new findings aim to address, offering a beacon of hope for a patient population with limited effective immunotherapy options.
Rigorous Research Uncovers Opposing Treg Cell Effects
To meticulously investigate the unique immune landscape of common colorectal cancers, the MSK team employed a sophisticated mouse model. This model was specifically engineered to closely mimic the genetic alterations, behavioral characteristics, and complex immune environment observed in human colorectal tumors, providing a robust platform for preclinical studies.
Through a series of detailed and elegant experiments, the researchers made a critical discovery: tumor-associated Treg cells could be definitively segregated into two principal groups based on their molecular profiles and functional roles.
One group was identified by its production of interleukin-10 (IL-10), a signaling molecule or cytokine known for its immunosuppressive and anti-inflammatory properties. These IL-10-positive Treg cells were found to play a decidedly beneficial role in the context of colorectal cancer. Their primary mechanism of action involves actively reducing the activity of Th17 cells, another type of immune cell that produces interleukin-17 (IL-17). Crucially, IL-17 acts as a growth signal, effectively promoting tumor proliferation. By dampening Th17 cell activity and IL-17 production, the IL-10-positive Tregs effectively slow tumor growth. These protective Treg cells were observed more frequently in the healthy tissue immediately adjacent to the tumor, suggesting a role in maintaining local immune homeostasis. When the researchers selectively removed these IL-10-positive Treg cells in their experimental models, a stark consequence was observed: tumors grew significantly more quickly, underscoring their protective function.
Conversely, the second group, IL-10-negative Treg cells, exhibited a detrimental effect on tumor control. These cells actively suppress the body’s most potent immune defenders, particularly CD8+ T cells, which are renowned for their direct cancer-fighting capabilities. By inhibiting CD8+ T cells, these harmful IL-10-negative Tregs create an environment conducive to tumor evasion and growth. Unlike their beneficial counterparts, this deleterious subtype was predominantly localized within the tumor itself, strategically positioned to neutralize anti-cancer immune responses. The selective elimination of these IL-10-negative Treg cells led to a dramatic and encouraging outcome: tumors became notably smaller, validating their role as drivers of tumor progression.
Patient Data Validates Preclinical Findings
To translate these compelling preclinical observations into human relevance, the MSK team meticulously confirmed their findings using actual tumor samples obtained from patients with colorectal cancer. Their analysis unequivocally identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells within human tumors, mirroring the patterns observed in the mouse models.
Further strengthening the clinical implications, the researchers conducted a comprehensive analysis of outcomes for over 100 colorectal cancer patients. The results were striking and statistically significant: patients whose tumors exhibited higher levels of the beneficial IL-10-positive Treg cells consistently demonstrated longer survival. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells experienced poorer outcomes.
"This research shows how important these positive cells are," affirms Dr. Huang. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment encapsulates the essence of precision immunology: moving beyond broad-stroke interventions to highly targeted strategies that leverage the immune system’s own intricate regulatory mechanisms.
Targeting CCR8: A Promising New Therapeutic Strategy
The profound insights gleaned from this study point toward a highly promising therapeutic avenue for improving treatment for the majority of colorectal cancer patients, particularly those with MSS/MMRp tumors. The researchers identified a crucial molecular marker: the harmful IL-10-negative Treg cells express exceptionally high levels of a specific protein called CCR8. Importantly, these CCR8-expressing cells are the very ones primarily located within tumors and are responsible for suppressing effective anti-tumor immune responses.
This discovery builds upon earlier, seminal work from Dr. Rudensky’s lab, led by breast cancer surgeon George Plitas, MD. Their previous research had already shown that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. That foundational work ignited the hypothesis that antibodies could be engineered to selectively target and deplete these CCR8-expressing harmful Treg cells. Such an approach would enable the immune system to mount a more robust and sustained attack against tumors, critically, without compromising the beneficial Treg cells that maintain healthy immune tolerance elsewhere in the body.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," emphasizes Dr. Rudensky, who is also a Howard Hughes Medical Institute Investigator. This statement underscores the widespread scientific and pharmaceutical interest in CCR8 as a universal target for enhancing anti-cancer immunity. Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously testing this innovative approach both as a standalone therapy and in combination with existing immunotherapies. The new study on colorectal cancer provides powerful preclinical and clinical validation, significantly strengthening the rationale for deploying this strategy in CRC and potentially far beyond.
Broader Implications: Similar Immune Patterns in Barrier Tissues
The MSK team’s investigations extended beyond colorectal cancer, probing a vast dataset of T cells derived from 16 different cancer types. Their goal was to ascertain whether the same nuanced immune patterns observed in CRC might manifest in other malignancies. Remarkably, they uncovered similar divisions between IL-10-positive and IL-10-negative Treg cells in several cancers affecting the skin and the delicate lining of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," notes Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This shared characteristic of "barrier tissues" – constantly interacting with the external environment and prone to inflammation – suggests a common immunological blueprint. The researchers posit that therapeutic strategies designed to remove IL-10-negative Treg cells in colorectal cancer could therefore hold significant promise for treating these other barrier-tissue cancers as well, opening up a broader therapeutic landscape.
A Different Immune Balance in Metastatic Disease
The research also delved into the complexities of metastatic colorectal cancer, specifically examining cases where the disease had spread to the liver. Here, the team observed a distinctly different immune pattern compared to primary tumors. In these advanced, metastatic lesions, the harmful IL-10-negative Treg cells were found to greatly outnumber their helpful IL-10-positive counterparts.
This altered immune landscape in metastatic disease led to a crucial experimental finding: unlike primary tumors, the complete removal of all Treg cells in this metastatic context resulted in the shrinkage of the tumors. This observation highlights the profound influence of disease stage and anatomical location on the tumor microenvironment and immune cell composition. The researchers stress that this finding underscores the imperative for developing treatment strategies that are not only tailored to the specific tissue involved but also finely tuned to the stage of the disease, moving towards increasingly personalized and adaptive cancer therapies.
Future Directions and Transformative Potential
This monumental study from MSK represents a profound leap forward in understanding the intricate dance between the immune system and cancer. By dissecting the once-paradoxical role of regulatory T cells in colorectal cancer, the researchers have illuminated a clear path toward more effective and precise immunotherapies. The identification of CCR8 as a specific marker for harmful Treg cells provides a tangible target for drug development, with CCR8-depleting antibodies already in clinical trials.
The implications are far-reaching: from transforming the treatment landscape for the majority of colorectal cancer patients who currently lack effective immunotherapy options, to offering new hope for individuals battling other cancers arising in barrier tissues. While the complexities of metastatic disease demand further nuanced approaches, this research firmly establishes the power of precision immunology. It heralds an era where therapies can be designed to selectively disarm cancer’s immune allies while empowering the body’s own defenses, moving us closer to a future where cancer is not just treated, but truly conquered.
Authors, Funding, and Disclosures:
Additional authors contributing to this research include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key institutional support was provided by the Integrated Genomics Operation and the Single Cell Research Initiative at MSK.
The study received generous funding from the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky serves on scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity.
Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8.
About the Author
